DARPA Ticks Insert Radioisotopes, Gain-And-Loss-Of-Function

by Dr. Ariyana Love

In my latest interview with Ann Vandersteele, I broke news about DARPA’s weaponized ticks containing radioisotopes, deadly parasites and bacteria.

Ann Vandersteel™️@annvandersteel

https://t.co/ojBAsY0v0E

6:12 PM · Jul 20, 2026 · 3.92K Views

2 Replies · 17 Reposts · 28 Likes

A recent CDC report estimates that a whopping 24% of adults in five high-risk states—Arkansas, Kentucky, Missouri, Tennessee, and Virginia—carry alpha-gal antibodies, indicating exposure to the sugar molecule that triggers alpha-gal syndrome.

Radioactive ticks have been used in two distinct contexts: scientific ecological studies involving radioisotope tagging to track movement, and alleged Cold War experiments where ticks were reportedly made radioactive to study dispersal or potentially used as biological weapons.

The Defense Advanced Research Projects Agency (DARPA) and the U.S. military’s bioweapons program, specifically at Rocky Mountain Laboratories, historically investigated the potential to enhance biological agents through radiation and microbial exposure to increase their lethality and resistance to pharmaceutical treatment. This lab also focuses on severe infectious diseases such as Ebola, Marburg, and COVID-19.

Declassified documents and investigations suggest that tick specimens were altered through radiation and microbial exposure prior to potential release, prompting allegations that these methods contributed to the spread of Lyme disease in the U.S.

The U.S. government holds patents on Lyme disease diagnostics and treatments (including vaccines), primarily managed by agencies such as the National Institutes of Health (NIH) and the Department of Energy (DOE).

Research funded by the DOE Office of Biological and Environmental Research and the NIH led to U.S. Patent 7,179,448 (issued 2007). While assigned to Brookhaven Science Associates (operated for the DOE), this patent covers chimeric proteins developed by scientists at Brookhaven National Laboratory and Stony Brook University for use in genetically engineered proteins (spike protein) in vaccines and diagnostic tests.

• Please read: Declassified Documents Link U.S. Bioweapons Program to Lyme Disease Outbreak — by Dr. Robert W. Malone.

The following U.S. Patent 7,179,448 is owned by the U.S. Government and demonstrates that a Gain-Of-Function biological weapon made of recombinant proteins from the Borrelia burgdorferi spirochete bacterium is being used in “vaccines.”

The patent is structured using a markup language for machine-readable format. In other words, it’s written in code, which makes it impossible for the layman to read. This is standard for classified military projects.

Loss-Of-Function mRNA Parasites

There are two tests used in Lyme’s Disease diagnostics. One test is used to identify SEQ ID No. 1, and the second test identifies Borrelia spirochetes.

U.S. Patent 9,816,991 is a Lyme Disease diagnostic peptide test for identifying SEQ ID No: 1, which uses genetically modified parasites as carriers of mRNA.

Lyme Disease is a GAIN-AND-LOSS-OF-FUNCTION bioweapon using mRNA parasites for genomic transfection (genetic modification) and Borrelia spirochetes. Knowing they’re testing people for mRNA parasites indicates these parasites are being used in weaponized ticks to weaken the population’s health and induce Lyme’s disease.

The following genetically attenuated mRNA carriers are found in the SEQ ID No:1 patent:

• Plasmodium falciparum: The first intraerythrocytic developmental cycle transcriptome was published for this malaria parasite. The reference sequence ID for Chromosome 1 of the Plasmodium falciparum 3D7 reference genome is NC_004325.

• Giardia intestinalis: The WB-C6 isolate (assemblage A1) is cited as the first genome sequenced for this species.

• Brugia malayi: This was the first parasitic nematode to have its genome fully sequenced.

• Encephalitozoon intestinalis: Recent single-cell RNA-seq studies have mapped its transcriptional dynamics in human macrophages.

• Trypanosoma Cruzi: The genome sequence for the Trypanosoma cruzi strain Bug2148 (the first genome sequenced for cluster TcV) is deposited in GenBank under the accession number NMZN00000000.

• Toxoplasma ghondi: The Whole Genome Shotgun project is deposited at DDBJ/EMBL/GenBank under the project accession LLKL01000000 (BioProject PRJNA294483). This project consists of individual sequence accessions ranging from LLKL01000001 to LLKL01000441.

Please see: GMO Parasites Are mRNA Vectors For Brain-Computer Interface.

Ticks naturally insert bacteria and parasites into their host via their saliva, so why not weaponize it?

U.S. Patent 10983121 is another diagnostic test entitled Compositions and methods for diagnosing Lyme disease and for predicting Lyme disease spirochete elimination after treatment. This test determines the production of a T-cell immune response indicator to the Borrelia spirochete bacteria. This is the Gain-of-Function culprit in Lyme disease.

Borrelia spp. are obligately parasitic, gram-negative spirochete bacteria characterized by their helically shaped, loosely coiled morphology and unique linear chromosomes with numerous plasmids. They are arthropod-borne, transmitted primarily by ticks (genera Ixodes, Ornithodoros, Argas) and body lice (Pediculus humanus), relying on blood-feeding vectors.

Spirochete infections present with symptoms that vary by the specific pathogen and stage of disease, but common early signs include flu-like illness (fever, chills, headache, myalgia, fatigue) and characteristic skin lesions.

The genus is divided into two key groups with distinct clinical profiles:

• Lyme Borreliosis Group: Includes Borrelia burgdorferi sensu lato, which causes Lyme disease (erythema migrans, arthritis, neuroborreliosis). These genetically modified bacteria are organotropic. They replicate and reside in tissues long after initial infections, developing cancer growth. Exposure is via “vaccines”.

• Relapsing Fever Group: Includes species causing tick-borne relapsing fever (e.g., B. hermsii) and louse-borne relapsing fever (B. recurrentis). These are characterized by high spirochaetemia and cyclical fevers due to antigenic variation of surface proteins.

The following patents are all weaponized, Gain-Of-Function Borrelia bacteria that are being used in “vaccinations” to induce Lyme’s Disease.

• U.S. Patent 8680236B2, which covers altered OspA proteins of Borrelia burgdorferi for improved vaccine efficacy and diagnosis.

• U.S. Patent 20010036658A1: Describes specialized culture media for growing spirochetes, including Borrelia subtypes.

• U.S. Patent 5434077A: Relates to specific **Borrelia burgdorferi strain 257 and its use in vaccine production.

• U.S. Patent 9670537B2: Pertains to a Borrelia provocation procedure kit for diagnostic purposes.

• U.S. Patent 20050042235A1: Concerns a Borrelia burgdorferi bacterin (vaccine) for veterinary or human use.

Now we have injectable Gain-of-Function jabs deceptively labeled “vaccines” and ticks released into the wild that carry these pathogenic lab poisons.

Bringhampton University reported in June that Ticks are ‘spreading like wildfire ’-and more of them are carrying Lyme.

DARPA has funded research into vaccines for tick-borne diseases, specifically the Crimean-Congo hemorrhagic fever virus, where insect vectors were weaponized under the guise of public safety. Crimean-Congo hemorrhagic fever virus (CCHFV) patents are primarily held by researchers at the Rocky Mountain Laboratories (part of the NIAID/NIH in the USA). This is a severe tick-borne bioweapon with a wide geographical distribution and case fatality rates of 30% or higher.

Mosquitos have also been weaponized by DARPA to genetically modify humans. The Chimeric chikungunya “virus” is not a “virus” at all. It’s a patented bioweapon, US8343506B2, using cDNA (complementary DNA) for the genetic modification of the human genome.

Read more about cDNA here: COVID-19 Patent Horrors.

The Alpha “virus” is in the Chimeric chikungunya “virus” and is a patented bioweapon, US8343506B2.

DARPA has played a critical role in developing mRNA “vaccines.” DARPA specifically funded Moderna’s mRNA-1944 to “combat” the mosquito-borne chikungunya “virus.” Incidentally, the chikungunya “virus” is in fact a chimeric mRNA parasite. It’s literally a patented bioweapon.

In 2025, a study titled Research progress of mosquito-borne virus mRNA vaccines was published on the NIH website, updating the progress of mRNA (parasite) “vaccines,” using lipid nanoparticles and polymer nanoparticles.

“These vaccines encode viral antigens (via mRNA parasites), which are translated into antigenic proteins within host cells.”

DARPA developed a way to genetically modify military personnel’s skin microbiome to “protect them from mosquitoes” in 2019. See the link here.

Other related DARPA initiatives mentioned include:

• Safe Genes: A project focused on using gene drive technology (CRISPR/Cas9) to control disease-causing mosquito populations.

• PREEMPT (Preventing Emerging Pathogenic Threats): A program funding research to modify mosquitoes.

• Insect Allies: A program mentioned in older contexts regarding using insects for biological applications, though details are sparse in the provided text.

DARPA has pursued two distinct initiatives involving mosquito surveillance and control: the Hybrid Insect MEMS (HI-MEMS) program and the ReVector program.

Please see: Luciferase Microarray Patches Contain DARPA Hydrogel & Autonomous Insect Cyborg Sentinels.

In 2019, Defense Advanced Research Projects Agency (DARPA) announced its ReVector program, which aims to diminish the olfactory attraction mosquitoes have to human skin by genetically engineering your skin’s microbiome.

DARPA created weaponized mosquitoes and ticks, while Moderna provides a new mRNA “vaccine” as the cure. So, the U.S. Government creates the problem, unleashing bioweapon ticks and mosquitoes on the American people, while Big Pharma (Moderna) gets to profit. Moderna’s supposed tick bite treatment is just more gene-silencing technology under the guise of a “vaccine.”

In 2019, DARPA funded a team led by Autonomous Therapeutics, Inc. and principal investigator Dr. Ariel Weinberger. This team included partners such as the CSIRO Australian Animal Health Laboratory and the Navy Medical Research Unit-2. The project focused on studying airborne and tick-borne “viruses,” including highly pathogenic avian influenza and Crimean-Congo hemorrhagic fever, under the guise of developing medical countermeasures.

A 2021 study published by the NIH titled Genetic Manipulation of Ticks: A Paradigm Shift in Tick and Tick-Borne Diseases Research explains how transgenic ticks are developed with the use of CRISPR/Cas9, the “most promising gene-editing approach for tick genetic transformation.”

CRISPR/Cas9 is the gene-editing tool being used in tick genetic transformation. The two primary methods used for weaponizing ticks are:

Embryo Injection: Researchers surgically removed the maternal Gené’s organ (which produces the waxy coating on eggs) and treated eggs with chemicals to lower pressure and remove the hard shell, allowing direct injection of the CRISPR complex.

ReMOT Control: A less labor-intensive method where CRISPR components are injected into adult female ticks. A specific peptide directs the Cas9 enzyme to the ovaries, editing the genome of the developing offspring.

“Microinjection into newly deposited arthropod eggs (embryos) allows modification of the embryonic germline before it has differentiated (prior to cellularization), ensuring a heritable modification ( Figure 1 ). Although approaches such as the gene gun (Thomas et al., 2001) and electroporation (Kamadar et al., 1992) have been tested in arthropods, embryo microinjection remains the most common approach for delivering gene-editing tools to the nucleus for genome modification. An embryo injection protocol was first established for the genetic transformation of D. melanogaster using transposable elements. This classical protocol (Rubin and Spradling, 1982) has been adapted to allow the injection of various types of nucleic acid constructs such as transformation vectors (P-elements, PiggyBac, Hermes, etc.) and their helper plasmids, RNA, single-guide RNA (sgRNA), plasmids, and Cas9 mRNA (or Cas9 protein).”

The genetic basis of Alpha-gal syndrome involves the GGTA1 gene, which encodes the enzyme alpha-1,3-galactosyltransferase in human cells after the weaponized tick bites. GGTA1 deletion is the basis for alpha-gal syndrome, a severe mammalian meat allergy.

A recent study, from July 6, 2026, reveals that deletion of the GGTA1 gene in humans induces alpha-gal meat allergy.

“GGTA1 gene deletion removes the synthesis of the $\alpha$-Gal epitope, a major carbohydrate antigen responsible for hyperacute rejection in pig-to-human xenotransplantation.

The GGTA1 gene encodes $\alpha$-1,3-galactosyltransferase, which produces the $\alpha$-Gal antigen on cell surfaces; its knockout prevents the binding of pre-existing human anti-Gal antibodies.”

Researchers used gene-edited GGTA1-deficient pigs as a translational model to study the immunopathogenic mechanisms of AGS, such as IgE sensitization and anaphylaxis, because their skin physiology and glycosylation patterns closely resemble those of humans.

GenCards explains how it’s gene silencing GGTA1 kit targets the human body:

“GGTA1 encodes an inactive glycosyltransferase related to alpha-1,3-galactosyltransferase activity, but the predicted protein lacks the C-terminal catalytic domain. It is classified in the glycosyltransferase 6 family and is present as a truncated, non-enzymatic form of the GGTA1 protein. Aberrant expression of GGTA1 in humans has been reported in connection with immune and tumor-related biology.

GGTA1 localizes to the Golgi cisterna membrane, Golgi cisterna, cytosol, and plasma membrane, placing it in compartments associated with intracellular processing and cell-surface biology. Expression measurements show high protein levels in the brain, endocrine system, and respiratory system, with RNA expression also detected in the cardiovascular system. The gene is noted in a leukotriene D4 biosynthetic process, providing a defined process-level context for its biological annotation.

Pathogenic or aberrant GGTA1 expression has been reported in autoimmune diseases and germ cell tumors. These clinical associations are the clearest disease-level links in the available evidence and frame GGTA1 as a gene of interest in immune dysregulation and tumor biology.”

Alpha-gal GGTA1 deletions in humans can lead to a complete shut down of the immune system (autoimmune diseases), and often germ cell tumors.

While Lyme’s Disease has been historically induced using mRNA parasites and gain-of-function bacteria, the new and improved ticks now contain radioisotopes.

Carbon-14 glucose, a radioisotope, has been infused into tick venom for the pleasure of burning people from the inside out. My clients, and other testimonials from people who’ve been bitten by DARPA’s weaponized ticks, are suffering radiation poisoning that present as painful, hot, red chemical burns that show up on the surface of their skin. It’s life-threatening torture.

Carbon-14 glucose is a synthetic radioisotope that penetrates organs and tissue and remains there as a forever chemical. It’s used to track synthetic and organic molecules and monitor cellular activity. The government is tracking people’s internal biometrics with this technology.

Unfortunately, the U.S. Government has been poisoning people with Carbon-14 radioisotopes in diagnostics, medicine, and cancer treatments. It’s also been slipped into dietary supplements and foods, as a “preservative.”

The CDC and NIH report that there’s no way to stop the replication of Carbon-14 glucose in organs and tissue. Since this is a Gain-And-Loss-Of-Function bioweapon, the U.S. Government is in violation of international law under the Chemical Weapons Convention (CWC) and the 1925 Geneva Protocol strictly ban the development, production, stockpiling, and use of chemical weapons.. This is a multilateral treaty that bans the development, production, stockpiling, and use of chemical weapons, requiring the destruction of all existing stocks.

DARPA’s weaponized ticks and mosquitos are life-threatening “weapons of mass destruction” and it’s an international threat.

If you are experiencing tick bite poisoning, please report it to the Organization for the Prohibition of Chemical Weapons (OPCW) in the Netherlands, for immediate investigation: T +31 70 416 3300.

Please also contact the National Response Center (NRC) at 1-800-424-8802. his hotline is staffed 24/7 by U.S. Coast Guard personnel and serves as the federal point of contact for such threats.

Additionally, if you suspect a terrorist event or have information regarding chemical weapons, you can contact the Federal Bureau of Investigation (FBI) at 1-202-324-3000 (Headquarters) or the Department of Justice Office for Domestic Preparedness helpline at 1-800-368-6498.

When Carbon-14 glucose replicates throughout organs and tissue, the process is life-threatening. The radiation is potentially deadly, the severe dehydration from radiation is deadly, and so is the Alpha-Gal meat allergy. It has to be treated as a forever chemical with detox and the reversal of cellular damage. The extreme dehydration that accompanies Carbon-14 glucose poisoning is also life-threatening. The gene deletion induced Alpha-Gal Syndrome can be life-threatening, if meat and dairy is consumed, bovine in particular.

Dr. Robert Young disclosed to me that MasterPeace has already been third-party tested and scientifically proven to remove strontium and the cesium 134 and 137 radioisotopes. Dr. Young did participate in some of the MasterPeace lab analysis, and he is certain that MasterPeace is antidotal to Carbon-14 glucose radioisotopes in DARPA’s tick venom bites.

I created an essential oil blend to help remove DARPA’s weapon system and reverse the cellular damage in the nervous system, organs and brain. Victims are reporting severe chemical radiation burns all over their skin, which accompanies Alpha-Gal.

My Radiation Defense essential oil (AM & PM) blend can also be used to shield and protect yourself from EMF and cell phone radiation poisoning, as it reverses and mitigates damage to cells. This product also cleanses parasites.

CILCK HERE if you wish to schedule a health consultation with me, you can do so through my Calendly booking page. I customize protocols and have a dietary protocol for people with Alpha-Gal.

Consider supporting my research by subscribing to my Substack Dr. Ariyana Love.